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Abstract
We present a nonparametric Bayesian
method for disease subtype discovery in
multi-dimensional cancer data. Our method
can simultaneously analyse a wide range
of data types, allowing for both agreement
and disagreement between their underlying
clustering structure. It includes feature
selection and infers the most likely number
of disease subtypes, given the data.
We apply the method to 277 glioblastoma
samples from The Cancer Genome Atlas, for
which there are gene expression, copy number
variation, methylation and microRNA data.
We identify 8 distinct consensus subtypes
and study their prognostic value for death,
new tumour events, progression and recur-
rence. The consensus subtypes are prognos-
tic of tumour recurrence (log-rank p-value of
3.6 × 10−4 after correction for multiple hy-
pothesis tests). This is driven principally
by the methylation data (log-rank p-value of
2.0× 10−3) but the effect is strengthened by
the other 3 data types, demonstrating the
value of integrating multiple data types.
Of particular note is a subtype of 47 patients
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characterised by very low levels of methy-
lation. This subtype has very low rates of
tumour recurrence and no new events in 10
years of follow up. We also identify a small
gene expression subtype of 6 patients that
shows particularly poor survival outcomes.
Additionally, we note a consensus subtype
that showly a highly distinctive data signa-
ture and suggest that it is therefore a biolog-
ically distinct subtype of glioblastoma.
We note that while the consensus subtypes
are highly informative, there is only par-
tial overlap between the different data types.
This suggests that when considering multi-
dimensional cancer data, the underlying biol-
ogy is more complex than a straightforward
set of well-defined subtypes. We suggest that
this may be a key consideration when mod-
eling such data.
The code is available from
https://sites.google.com/site/multipledatafusion/
1. Introduction
Cancer is a complex disease, driven by a range of ge-
netic and environmental effects. It is responsible for 1
in 8 deaths worldwide (ACS, 2011), with an estimated
7.6 million cancer deaths worldwide in 2008 (Jemal
et al., 2011). Understanding the cancer genome (Strat-
ton et al., 2009) and the associated molecular mech-
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anisms is therefore a vitally important global medical
issue.
Modern large-scale cancer studies present great new
opportunities to understand different types of can-
cer and their underlying mechanisms. Projects
such as The Cancer Genome Atlas (TCGA)
(http://cancergenome.nih.gov/) and METABRIC
(Curtis et al., 2012) and the International Cancer
Genome Consortium (ICGC, 2010), are producing
large, multi-dimensional data sets that have the
potential to revolutionise the study of cancer.
One of the first TCGA projects is a study of glioblas-
toma, (TCGA, 2008) the most common primary brain
tumour in human adults. Glioblastoma is an aggres-
sive cancer; patients with newly diagnosed glioblas-
toma have a median survival of ≈ 1 year. The TCGA
glioblastoma data set is a hugely relevant resource for
improving this situation.
Key to the utilisation of these multi-dimensional data
sets is to develop effective data fusion methods (see e.g.
Shen et al., 2009; Savage et al., 2010; Yuan et al., 2011;
Kirk et al., 2012). It is not enough to simply concate-
nate the different data types; one must account for the
different statistical characteristics of each data type
and that they may contain differing or even contra-
dictory information about the samples studied. There
is potentially huge benefit to proper analysis of such
multi-dimensional data sets (e.g. consider the number
of pairwise data type comparisons as the total number
of types increases). But to fully realise this, we must
develop new methods.
The Multiple Data Integration (MDI) algorithm (Kirk
et al., 2012) is a principled framework for the iden-
tification of cancer subtypes. It can analyse multi-
dimensional data sets, combining a range of individual
data types such as gene expression, copy number varia-
tion, methylation and microRNA data. MDI can be re-
garded as the extension to multiple (possibly disagree-
ing) data types of nonparametric Bayesian clustering
methods such as the Dirichlet Process (DP) mixture
model (see e.g. Ferguson, 1973; Antoniak, 1974; Esco-
bar & West, 1995; Dahl, 2006; Rasmussen et al., 2007).
The key advantage of MDI is that it allows for the pos-
sibility of both agreement and disagreement between
the clustering structures of different data types within
a given analysis. This is extremely important in bi-
ological data sets. For example, gene expression can
be regulated by a number of biological mechanisms,
so is not determined solely by the underlying genome.
Hence integrating gene expression and copy number
variation data might or might not result in good agree-
ment, depending on the biological context.
MDI produces clustering partitions for each data type,
as well as an overall consensus clustering partition. It
also identifies the degree to which different data types
share common structure, and can identify which of the
items are fused across the different data types.
To extend the MDI method to the analysis of cancer
data, we have added additional functionality beyond
that of Kirk et al. (2012) Two data models (Gaussian
and Multinomial) are used. For each of these data
models, feature selection has been added, so that the
most informative features can be identified for each
data type. Additionally, it is known that the MCMC
chains in mixture-based clustering methods can be
slow to mix when using a Gibbs sampler. To improve
performance in this regard, an additional split-merge
MCMC sampler has been added, which is used in con-
junction with the existing Gibbs steps.
MDI therefore has the following advantage in
analysing post-genomic molecular cancer data.
• Infers (Rather than assumes) the degree to which
clustering structure is shared between data types
• Infers the likely number of clusters given the data
• Identifies the genes/probes in each data type that
define the disease subtypes
• Integrate simultaneously a wide range of data
types (4 in this paper; more can easily be included
if available)
The rest of the paper is summarised as follows. In
Section 2 we describe the data set. In Section 3 we
describe MDI and present several improvements to
the method. In Section 4 we present the results of
analysing the TCGA glioblastoma data. Finally, in
Section 5 we draw conclusions about this work.
2. Data
We downloaded glioblastoma data (TCGA,
2008) from the TCGA data portal
(http://cancergenome.nih.gov/ ), including gene
expression, copy number variation, methylation
and microRNA data, as well as clinical follow-up
information. After matching samples across all 4 data
types, we are left with 277 samples for which we have
complete data. We note that in a few cases (and for
a given data type) there are duplicate samples for the
same patient. In this case we make a blind selection
of the first sample, based on bar code ordering.
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All data were downloaded from the TCGA data portal
on 13th April 2012.
2.1. Gene Expression
We use the publicly-available level 3 gene expression
data. For consistency, data were chosen from a single
platform. The UNC AgilentG4502A 07 samples were
selected as they were most numerous, giving a total
of 571 tumour samples. These were read into a single
data matrix and NaN (missing) values set to zero.
The data include 10 normal samples. For each gene,
a Wilcoxon rank-sum test was used to determine
whether or not there was differential expression be-
tween tumour and normal samples. A Bonferroni
correction and p-value threshold was applied (p <
2× 10−3), leaving 1011 gene expression features.
2.2. Copy Number Variation
We use the publicly-available level 2 copy number
data. We chose level 2 so that we had access to all
probes (the level 3 data are segmented into regions
which, in general, are different from sample to sam-
ple). This gave 466 tumour and 376 normal samples
generated by MSK C using the HG-CGH-244A plat-
form. These were read into a single data matrix and
NaN (missing) values set to zero.
For each probe, a Wilcoxon rank-sum test was used
to determine whether or not there was differential
copy number variation between the normal and tu-
mour samples. A Bonferroni correction was then ap-
plied to the p-values. A large number of probes had
highly significant p-values, many of which contained
similar information. It was therefore decided on prac-
tical grounds to keep only the 1000 most significant
probes as features for this analysis.
2.3. Methylation
We use the publicly-available level 3 methylation data.
This gave 285 samples generated by JHU-USC on
the HumanMethylation27 platform. The data were
in the form of beta values, which measure the ratio of
methylation signal to (methylation + background) sig-
nal. For convenience, the data were binarised using a
threshold of β > 0.95. Features containing fewer than
10 hits were then removed, leaving 769 features.
2.4. Micro RNA
We use the publicly-available level 3 microRNA data.
This gave 490 tumour samples generated by UNC on
the H-miRNA 8x15K platform.
The data include 10 normal samples. For each mi-
croRNA in turn, a Wilcoxon rank-sum test was used to
determine whether or not there was differential expres-
sion between tumour and normal samples. Applying
a Bonferroni correction and then keeping only genes
with a p-value of p < 1× 10−3 gave us 104 features.
2.5. Clinical Follow-up
The corresponding clinical data were also downloaded.
The files follow up v1.0 public GBM.txt and clini-
cal patient public GBM.txt were used, matching the
patients on the basis of the TCGA bar codes. We
note that 51 of the 277 samples did not have complete
clinical follow-up information.
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The outline of this paper is as follows. In Section 2, we briefly
provide some modelling background and present our approach.
Inference in our model is performed via a Gibbs sampler, which
is provided in the Supplementary Material. In Section 3, we
describe three case study examples, in all of which we use publicly
available S. cerevisiae (baker’s yeast) datasets. We then present
results (Section 4), and provide a discussion in Section 5.
2 METHODS
In this section, we provide some background regarding Dirichlet-
multinomial allocation mixture models (Section 2.1), and consider how
these may be extended to allow us to perform integrative modelling of
multiple datasets (Section 2.2). Inference in the resulting model (which
we shall henceforth refer to as MDI) is performed using a Gibbs sa pler
(see Supplementary Material). We briefly describe in Section 2.4 how the
resulting posterior samples may be effectively summarised.
2.1 Dirichlet-multinomial allocation mixture models
We model each dataset using a finite approximation to a Dirichlet process
mixture model (Ishwaran and Zarepour, 2002), known as a Dirichlet-
multino ial allocation mixtu model (Green a d Richardson, 2001). Such
models have the following general form:
p(x) =
N∑
c=1
picf(x|θc). (1)
Here,N is the aximum number of mixture components, pic are the mixture
proportions, f is a parametric density (such as a Gaussian), and θc are
the parameters associated with the c-th component. Importantly, different
choices for the density f allow us to model different types of data (for
example, a normal distribution might be appropriate for continuous data,
while a multinomial ight be appropriate for categorical data).
Given observed data x1, . . . , xn, we wish to perform Bayesian inference
for the unknown parameters in this model. We introduce latent component
allocation variables cj ∈ {1, . . . , N}, such that ci is the component
responsible for observation xi. We then specify the model as follows:
xi|ci,θ ∼ F (θci ),
ci|pi ∼ Multinomia (pi1, . . . , piN ),
pi1, . . . , piN ∼ Dirichlet(α/N, . . . , α/N), (2)
θc ∼ G(0),
where F is the distribution corresponding to density f , pi = (pi1, . . . , piN )
is the collection of N mixture proportions, α is a mass/concentration
parameter (which may also be inferred), and G(0) is the prior for
the component parameters. Bayesian inference for such models may be
performed via Gibbs sampling (Neal, 2000). Note that a realisation of
the collection of component allocation variables, (c1, . . . , cn), defines a
clustering of the data (i.e. if ci = cj , then xi and xj are clustered together).
Since each cj is a member of the set {1, . . . , N}, it follows that the value
of N places an upper bound on the number of clusters in the data.
The Dirichlet process mixture model may be derived by considering the
limitN →∞ in Equation (1) (Neal, 1992; Rasmussen, 2000). In the present
paper, it is convenient to persist with finiteN (see Section 2.2). SinceN just
places an upper bound on the number of clusters present in the data, this is
not overly restrictive. Provided N is taken sufficiently large, the number of
clusters present in the data will be (much) less thanN , and we will retain the
ability to identify automatically the number of clusters supported by the data.
A choice of N = n states that the maximum possible number of clusters is
equal to the number of genes. As a tradeoff with computational cost, we take
N = dn/2e throughout this paper.
2.2 Dependent component allocations
We are interested in the situation where we have a collection of n genes, for
each of which we have measurements from K different data sources. One
possible modelling approach would be to fit K independent DMA mixture
models, represented graphically in Figure 1a for the case K = 3. However,
this neglects to consider (and fails to exploit) structure within the data that
may be common across some or all of the different sources. For example,
a set of co-regulated genes might be expected to have similar expression
profiles, as well as having a common collection of proteins that bind their
promoters. We therefore propose a model in which we allow dependencies
between datasets at the level of the component allocation variables, ci.
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Fig. 1: Graphical representation of K = 3 DMA mixture models.
(a) Independent case. (b) Modelling dependence between the latent
component allocation variables (the MDI model).
We consider K mixture models (one for each data set), each defined as
in Equations (1) and (2). We add right subscripts to our previous notation
in order to distinguish between the parameters of the K different models
(so that αk is the mass parameter associated with model k, etc.) and take
Nk = N in all mixture models. Note that each model is permitted to have
a different mass parameter, αk . MDI links these models together at the level
of the component allocation variables via the following conditional prior:
p(ci1, ci2, . . . , ciK |φ) ∝
K∏
k=1
picikk
K−1∏
k=1
K∏
`=k+1
(1 + φk`I(cik = ci`)) ,
(3)
where I is the indicator function, φk` ∈ R≥0 is a parameter that controls the
strength of association between datasets k and `, and φ is the collection of
allK(K−1)/2 of the φk`’s. For clarity, note that cik ∈ {1, . . . , N} is the
component allocation variable associated with gene i in model k, and that
picikk is the mixture proportion associated with component cik in model k.
Informally, the larger φk`, the more likely it is that cik and ci` will be the
same, and hence the greater the degree of similarity between the clustering
structure of dataset k and dataset `. In Figure 1b, we provide a graphical
representation of our model in the case K = 3. If all φk` = 0, then we
recover the case of K independent DMA mixture models (Figure 1a). Note
that (1+φk`I(cik = ci`)) ≥ 1, hence if φk` > 0 then we are up-weighting
the prior probability that cik = ci` (relative to the independent case).
Linking the mixture models at the level of the component allocation
variables provides us with a means to capture dependencies between the
datasets in a manner that avoids difficulties associated with the datasets being
of different types and/or having different noise properties. An important
2
Figure 1. Graphical representation of K = 3 DMA mix-
ture models. (a) Independent case. (b) Modelling depen-
dence between the latent component allocation variables
(the MDI model). Figure from Kirk et al. (2012)
3. Model
We further develop the Multiple Data Integration
(MDI) method of Kirk et al. (2012). MDI can be
regarded as an extension of nonparametric Bayesian
clustering methods to analyse simultaneously multiple
data types, inferring the degree of similarity between
the clustering structure in the data types. MDI hence
produces clustering partitions for each data type, as
well as an overall consensus clustering partition.
We note that another particular strength of MDI is
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that it infers the posterior distribution over the num-
ber of clusters in each data type. Hence, we can infer
the likely number of clusters, given the data. Many
clustering algorithms do not provide a method for do-
ing this, which is a major shortcoming.
3.1. The MDI model
We consider a multi-dimensional data set, consisting
of K distinct data types (for example, gene expression,
copy number, methylation or microRNA expression).
Each data type will contain measurements for the same
set of items, so that for each items we have K vectors
of measurements. We note that in general the numbers
of features for each data type will be different from one
another, and can be arbitrarily so for the MDI model.
We model each data type using a finite approxima-
tion to a Dirichlet process mixture model (Ishwaran
& Zarepour, 2002), known as a Dirichlet-Multinomial
Allocation (DMA) mixture model (Green & Richard-
son, 2001). The K DMA models are coupled by a set
of φ parameters that allow for information-sharing be-
tween the data types and provide a measurement of
the level of similarity between pairs of types. Figure 1
shows a graphical representation of the MDI model.
The DMA mixture model for a single data type is given
by the following equation.
p(x) =
N∑
c=1
picf(x|θc). (1)
Where pic are the mixture proportions, f is a paramet-
ric density (such as a Gaussian) that models the c-th
data type, and θc are the parameters associated with
the c-th component. N is the maximum number of
mixture components, which is set typically to be large
enough so as to not impact on the inference. When N
is large in this way, the behaviour of the DMA model
approaches that of a Dirichlet process. To ensure this
and as a tradeoff with computational cost, N = dn/2e
throughout this paper.
We note that different choices for the density f allow
us to model different types of data (for example, a
normal distribution might be appropriate for contin-
uous data, while a multinomial might be appropriate
for categorical data). This imparts great flexibility to
the MDI model.
Given observed data x1, . . . , xn, we wish to perform
Bayesian inference for the unknown parameters in this
model. We introduce latent component allocation vari-
ables cj ∈ {1, . . . , N}, such that ci is the component
responsible for observation xi. We then specify the
model as follows:
xi|ci,θ ∼ F (θci),
ci|pi ∼ Multinomial(pi1, . . . , piN ),
pi1, . . . , piN ∼ Dirichlet(α/N, . . . , α/N), (2)
θc ∼ G(0),
where F is the distribution corresponding to density
f , pi = (pi1, . . . , piN ) is the collection of N mixture pro-
portions, α is a mass/concentration parameter (which
may also be inferred), and G(0) is the prior for the
component parameters.
Now considering the full MDI model with K distinct
data types, to couple the K mixture models, the fol-
lowing conditional prior is introduced for the compo-
nent allocation variables.
p(ci1, . . . , ciK |φ) ∝
K∏
k=1
picikk
K−1∏
k=1
K∏
`=k+1
(1 + φk`I(cik = ci`)) ,
(3)
where I is the indicator function, φk` ∈ R≥0 is a pa-
rameter that controls the strength of association be-
tween datasets k and `, and φ is the collection of all
K(K − 1)/2 of the φk`’s. cik ∈ {1, . . . , N} is the com-
ponent allocation variable associated with item i in
model k, and picikk is the mixture proportion associ-
ated with component cik in model k. Informally, the
larger φk`, the more likely it is that cik and ci` will
take the same value, and hence the greater the de-
gree of similarity between the clustering structure of
dataset k and dataset `. If all φk` = 0, then we recover
the case of K independent DMA mixture models (Fig-
ure 1b). We constrain the φk` to be non-negative.
We note that the xij are assumed to be independent,
given the clustering in MDI. The model then concen-
trates on modeling the joint distribution of the allo-
cation variables ci1, ..., ciK which induces correlation
over the x’s.
3.2. Data Models
For the analyses in this paper, we use two different
densities, fGaussian and fmultinomial. These are re-
spectively used for real-valued and discrete data and
make reasonable assumptions (for the data used in this
paper) about the expected noise characteristics.
For both data models, we assume that the features
represent repeated, independent measurements of the
underlying clustering partition. We therefore have the
following equation.
f =
∏
a
fa (4)
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For the Gaussian density, we assume that each feature
is modeled by a Gaussian likelihood of unknown mean
and precision, subject to a Normal-Gamma prior.
There density is therefore closed form and we hence
marginalise the mean and precision.
We therefore have the following (marginal) likelihood
function for the Gaussian case.
fa,Gaussian =
Γ(αn)
Γ(α0)
βα00
βαnn
(
κ0
κn
)
1
2 (2pi)−
n
2 (5)
Where
µ ∼ N(0, (κ0λ)−1) (6)
λ ∼ Ga(α0, β0) (7)
κn = κ0 + n (8)
αn = α0 +
n
2
(9)
βn = β0 +
1
2
n∑
i=1
(x− x¯)2 + κ0nx¯
2
2κn
(10)
We set the Normal-Gamma hyperparameters to α0 =
2, β0 = 0.5 and κ0 = 0.001.
For the multinomial density, we assume that each fea-
ture is modeled by a multinomial likelihood, subject to
a Dirichlet prior. The parameters of the multinomial
likelihood are unknown, but because of the conjugate
prior the density has a closed form and those param-
eters can hence be marginalised, leaving only the hy-
perparameters βrq to be defined.
We therefore have the following (marginal) likelihood
function for the multinomial case.
fa,multinomial =
Q∏
q=1
Γ(Bq)
Γ(Sq +Bq)
R∏
r=1
Γ(xrq + βrq)
Γ(βrq)
(11)
We set the Dirichlet prior hyperparameters to βrq =
0.5.
3.3. Feature Selection
Because of the potentially large number of features
in the various omic data types, we extend the Gaus-
sian and multinomial data models to include feature
selection. To do this, we include binary indicator pa-
rameters Ia for each feature in a given data type. This
modifies Equation 4 to the following:
f =
∏
a
(Iafa) + (1− Ia)fa,null (12)
The factor for each feature will therefore either be fa
or fa,null. The fa are as before, so if all Ia = 1 then
we have the model with no feature selection.
The fa,null represent the alternative model that the
feature is uninformative and hence all items are mod-
eled as belonging to a single mixture component. We
also make an approximation that the likelihood pa-
rameters are known, rather than marginalised over.
This makes only a modest correction to the typical
marginal likelihood values, but significantly speeds up
the computation of the conditional distributions for
Gibbs resampling.
For data models taking the form in Equation 4, we
note that the distributions for Gibbs resampling of the
Ia are conditionally independent, given the cik. As
MDI is written in Matlab, this allows us to vectorise
the computation of the conditional distributions for
the Gibbs resampling of all the Ia. This vectorisation
makes the feature selection in MDI highly computa-
tionally efficient and fast to execute.
3.4. Split-Merge MCMC sampling
One characteristic of Gibbs samplers for mixture
model clustering algorithms is that the MCMC chains
can be relatively slow to mix. We have noticed this in
particular for the number of occupied components.
To improve this, we have implemented a version of the
sequential split-merge MCMC sampler of Dahl (2005).
The split-merge steps are applied separately to each
of the K DMA models. These MCMC steps are pro-
posed in addition to all the usual Gibbs steps described
in Kirk et al. (2012). The increase in computation re-
quired for the split-merge steps is minor, and we find
that while the acceptance rate for the steps is low, the
overall effect is to substantially improve the mixing
rate for the number of clusters for each data type.
3.5. Extraction of Clustering Partitions
We adopt a different approach to that of Kirk
et al. (2012) to the extraction of clustering parti-
tions from the posterior similarity matrix. Because
the previously-used method (Fritsch & Ickstadt, 2009)
is only available as an R package, for convenience we
implement as part of the MDI code a simpler method
based on a hierarchical clustering using the posterior
similarity matrix. We note that the results in Fritsch
& Ickstadt (2009) show that this approach produces
similar performance to the previously-used method.
Using as distances (1 - posterior similarity), we per-
form standard hierarchical clustering with complete
linkage. We set the number of clusters to be the MAP
estimate of the number of clusters, taken from the
MCMC analysis.
The resulting clustering partition should be regarded
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as a convenient summary of the full results. We would
strongly encourage users of this method to not neglect
other outputs such as the posterior similarity and fu-
sion matrices.
4. Results
We analyse gene expression, copy number variation,
micro-RNA and methylation data for 277 glioblastoma
patients using MDI. We identify a range of distinct
disease subtypes and results, the most interesting of
which we now describe.
Complete results can be found at
https://sites.google.com/site/multipledatafusion/
We consider 5 distinct cases of summarising cluster-
ing partition (for each individual type, and also the
consensus of all 4). For these we consider 4 binary,
right-censored clinical outcomes: death, new tumour
event, tumour progression, tumour recurrence. This
gives us 20 cases in all.
For each case, we plot the Kaplan-Meier survival
curves for the set of disease subtypes. Table 1 shows
the log-rank p-values for these plots, after application
of a Bonferroni correction for multiple hypothesis test-
ing (nTests=20). Examples of these plots can be seen
in Figure 4. We note that in all cases we only con-
sider subtypes containing at least 5 items and we only
consider items for which there is clinical outcome in-
formation.
4.1. Consensus subtypes are prognostic for
tumour recurrence
We note that the consensus subtypes in general are
strongly prognostic for tumour recurrence (log-rank
p-value of 3.6× 10−4 after correction for multiple hy-
pothesis tests) (see Figure 7). Because the methyla-
tion status is measured at the point of diagnosis, this
prognostic capability is predictive.
4.2. Interesting low-methylation subtype
Consensus subtype 7 has particularly interesting char-
acteristics. Comprising 47 items, it shows only very
low levels of tumour recurrence (see Figure 4) and no
new tumour events. All items in this subtype show
very low relative levels of methylation (see Figure 6).
This subtype contains 23 women and 24 men, with a
median age of 53 and an age range of 14 to 81.
4.3. Gene expression subtypes are prognostic
for survival outcome
Figure 5 shows the Kaplan-Meier survival curves for
the 8 gene expression (GE) subtypes identified by
MDI. These subtypes are prognostic for survival out-
come (log-rank p-value of 1.5 × 10−3 after correction
for multiple hypothesis tests).
This result is largely driven by GE cluster 7, which
consists of 6 patients with particularly poor survival
outcome (see Figure 5). Of these 6 patients, 3 die
within 6 months of diagnosis, and the other 3 are omit-
ted from the survival analysis as we do not have infor-
mation on their survival or otherwise (they are missing
data). As such, this result relies on a small number of
patients and should therefore be treated with caution.
However, further study is certainly warranted in case
this subtype remains distinct with a larger number of
members.
4.4. Partial overlap of clustering structure for
different data types
The fusion matrix (Figure 2 ) and consensus cluster-
ing results show that there is a level of consistency
in the clustering structure across the gene expression,
copy number variation, methylation and microRNA
data. However, inspection of the clustering partitions
for each data type show that there are also differences
in structure between each type. This indicates that a
single clustering partition is not sufficient to capture
all of the structure contained in the 4 data types.
4.5. Evidence for a biologically distinct
glioblastoma subtype
Consensus cluster 5 consists of 8 patients and is
noteworthy for highly distinctive data signatures in
gene expression (over-expression), copy number (ex-
cess copies) and micro-RNA (over-expression in a sub-
set of selected features).
This subtype is poor for tumour recurrence, and we
suggest that the striking data signatures are suggestive
of a distinctive set of biological mechanisms driving
this tumour subtype.
4.6. Fusion matrix makes biological sense
The φk` parameters provide information on the level
of agreement about clustering structure between pairs
of data types. Figure 2 shows the posterior mean val-
ues for the φk`. The principal sharing of structure is
shown to be between gene expression and the other
three data types, while other pairs of data types are
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Table 1. Bonferroni-corrected p-values for subtype Kaplan-Meier survival curves (nTests=20) For a given clinical outcome
and data type/s, the Kaplan-Meier curves for each disease subtype are produced. P-values are computed using the log-rank
test and considering the null hypothesis that all curves in a given set are drawn from the same underlying distribution.
data type/s died new event progression recurrence
all 1 0.66 0.11 3.6× 10−4
copy number 1 1 1 1
gene expression 1.5× 10−3 1 1 1
methylation 1 0.28 1 2.0× 10−3
microRNA 1 1 1 1
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Figure 2. Matrix showing the posterior mean values for the
φk`. Shown are the copy number data (row 1), gene ex-
pression (row 2), methylation (row 3), microRNA (row 4).
We note that the diagonal elements are undefined for the
MDI model and so are set to arbitrary values so as to make
the colour table convenient.
less strongly related. This confirms what would be ex-
pected from prior knowledge of the underlying biolog-
ical mechanisms. This is an important sanity check of
the analysis, and shows that there is useful biological
information in the data set.
4.7. MCMC details
The results presented in this paper are the result of 25
MCMC chains, each of ≈ 70, 000 samples. We sparse-
sample the chains by a factor of 10 and remove the first
25% of each chain as burn-in. We check for adequate
convergence by visual inspection of the MCMC time-
series and histograms for each chain, overlaid on one
another.
5. Conclusions
We have presented extensions to the MDI method
that make it suitable for analysing multi-dimensional
molecular cancer data sets. Using MDI to analyse the
TCGA glioblastoma data, we have identified a number
of important points.
Figure 3. Posterior similarity matrix for the 277 data
items. This matrix gives the posterior probability of given
pairs of items belonging to the same cluster, averaged over
the 4 data types. This is used to produce the consen-
sus clustering partition. The matrix shown here has been
sorted by the resulting partition, to better show the struc-
ture. The x-axis is labelled by alternating sets of bars/dots,
denoting the different clusters. The LHS y-axis bars show
the relative probability that a given item has the same
cluster label across data types.
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• Both the 8 methylation and 8 data-consensus dis-
ease subtypes we have identified are significantly
prognostic of tumour recurrence
• The 8 gene expression disease subtypes we have
identified are significantly prognostic of survlval
outcome
• We have identified a strongly prognostic glioblas-
toma subtype, noteworthy for its low levels of tu-
mour recurrence methylation
• We have identified a small subtype of 6 patients
based on gene expression for which there is very
poor survival outcome, and postulate that this
may identify a rare and agressive form of glioblas-
toma
• We have also identified a subtype of 8 patients
with a highly distinctive data signature. This
subtype has poor tumour recurrence, and it may
represent a subtype whose underlying biology is
highly distinctive, which may allow for more tar-
getted therapy
• We note that the clustering structures for the 4
different data types overlap partially, but there is
significantly more structure than can be explained
by a single partition
Modern, large-scale cancer data sets contain a wealth
of data types measuring the effects of genomic and
environmental processes. We have demonstrated the
effectiveness of combining these data types into a sin-
gle analysis, and shown that the richness of structure
contained by such multi-dimensional data sets neces-
sitates statistical methods capable of capturing that
richness.
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Figure 4. Kaplan-Meier survival curves plotting tumour recurrence for the consensus disease subtypes. The p-value is
computed using a log-rank test. When quoted in Table 1, a Bonferroni correction has been applied to account for multiple
hypothesis tests.
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Figure 5. Kaplan-Meier survival curves for the gene expression disease subtypes. The p-value is computed using a log-rank
test. When quoted in Table 1, a Bonferroni correction has been applied to account for multiple hypothesis tests.
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Figure 6. The mean number of methylated sites in each consensus subtype (out of a possible 769). A site is counted as
methylated if it has been binarised to have unit value in the input methylation data in this analysis.
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Figure 7. Plot of the 4 data types. The x-axis gives the data items (patients/tumour samples), sorted by the consensus
clustering partition. The y-axis gives the selected features for each data type, with the dashed lines on the LHS indicating
P(selected) for each feature. We note that any feature with P(selected)<0.1 is excluded from this plot, and also that the
outlying 5% of pixels in each data type are clipped for the purposes of plotting.
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